Fortis Capital Advisors LLC Acquires Shares of 2,221 HCA Healthcare, Inc. $HCA

Key Points

• Fortis Capital Advisors LLC recently acquired 2,221 shares of HCA Healthcare, Inc., valued at approximately $767,000, as reported in their latest 13F filing.
• HCA's recent quarterly earnings showed a net revenue of $18.61 billion with an earnings per share (EPS) of $6.84, surpassing analysts' expectations.
• The company announced a quarterly dividend of $0.72, which will be paid on September 30th, and has an annualized yield of 0.7%.

Fortis Capital Advisors LLC acquired a new stake in HCA Healthcare, Inc. (NYSE:HCA - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 2,221 shares of the company's stock, valued at approximately $767,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in HCA. Cheviot Value Management LLC purchased a new position in HCA Healthcare in the 1st quarter valued at $26,000. Saudi Central Bank purchased a new position in HCA Healthcare in the 1st quarter valued at $26,000. WPG Advisers LLC purchased a new position in shares of HCA Healthcare during the 1st quarter worth $27,000. Atwood & Palmer Inc. purchased a new position in shares of HCA Healthcare during the 1st quarter worth $28,000. Finally, Bartlett & CO. Wealth Management LLC raised its holdings in shares of HCA Healthcare by 888.9% during the 1st quarter. Bartlett & CO. Wealth Management LLC now owns 89 shares of the company's stock worth $31,000 after acquiring an additional 80 shares during the period. Hedge funds and other institutional investors own 62.73% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on HCA. Wolfe Research lowered HCA Healthcare from an "outperform" rating to a "peer perform" rating in a report on Monday, July 28th. Wall Street Zen upgraded HCA Healthcare from a "hold" rating to a "buy" rating in a report on Saturday, July 5th. Barclays cut their price objective on HCA Healthcare from $416.00 to $390.00 and set an "overweight" rating for the company in a research report on Monday, July 28th. Morgan Stanley cut their price objective on HCA Healthcare from $410.00 to $400.00 and set an "equal weight" rating for the company in a research report on Monday, July 28th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $444.00 target price on shares of HCA Healthcare in a research report on Tuesday, August 26th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and nine have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $403.17.

HCA Healthcare Price Performance

HCA stock opened at $394.00 on Thursday. The company has a quick ratio of 0.86, a current ratio of 0.98 and a debt-to-equity ratio of 69.07. HCA Healthcare, Inc. has a fifty-two week low of $289.98 and a fifty-two week high of $420.98. The business has a 50 day moving average price of $381.63 and a 200 day moving average price of $361.70. The stock has a market cap of $92.19 billion, a price-to-earnings ratio of 16.56, a PEG ratio of 1.30 and a beta of 1.41.

HCA Healthcare (NYSE:HCA - Get Free Report) last issued its quarterly earnings data on Friday, July 25th. The company reported $6.84 earnings per share for the quarter, beating analysts' consensus estimates of $6.20 by $0.64. HCA Healthcare had a negative return on equity of 7,363.11% and a net margin of 8.21%.The company had revenue of $18.61 billion during the quarter, compared to analysts' expectations of $18.49 billion. During the same quarter in the previous year, the business earned $5.50 earnings per share. The firm's revenue for the quarter was up 6.4% on a year-over-year basis. HCA Healthcare has set its FY 2025 guidance at 25.500-27.000 EPS. Equities research analysts anticipate that HCA Healthcare, Inc. will post 24.98 earnings per share for the current fiscal year.

HCA Healthcare Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Tuesday, September 16th will be paid a $0.72 dividend. The ex-dividend date is Tuesday, September 16th. This represents a $2.88 dividend on an annualized basis and a yield of 0.7%. HCA Healthcare's payout ratio is currently 12.11%.

Insider Activity

In other news, EVP Michael S. Cuffe sold 3,836 shares of the business's stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $418.84, for a total value of $1,606,670.24. Following the transaction, the executive vice president owned 31,503 shares of the company's stock, valued at approximately $13,194,716.52. The trade was a 10.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 1.30% of the company's stock.

HCA Healthcare Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.

Want to see what other hedge funds are holding HCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HCA Healthcare, Inc. (NYSE:HCA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.